eXmoor Pharma and Evox Therapeutics have completed a technology transfer program for Evox’s exosome-enabled gene editing platform, including its MSH3-targeted program for Huntington’s disease, at eXmoor’s Bristol, UK facility.
The initiative transferred and established Evox’s proprietary manufacturing process and associated analytical methods within eXmoor, an integrated cell and gene therapy CDMO with embedded consultancy expertise. Completion of this phase lays the technical groundwork for subsequent transfer into GMP operations and future clinical manufacturing. Evox is developing a pipeline of next-generation gene editing medicines for genetically driven neurodegenerative conditions such as Huntington’s disease and amyotrophic lateral sclerosis.
Exosome-delivered gene editing therapeutics represent an emerging class of biologics, and the program underscores the growing need to convert novel platforms into scalable, clinically relevant manufacturing processes. By embedding Evox’s process at eXmoor’s site, the partners aim to support the clinical development of exosome-based therapies with industrially robust production and testing capabilities.
eXmoor Chief Executive Officer Lucy Foley said that translating a novel platform into a robust, manufacturable process demands fully integrated process development, analytical development, and manufacturing expertise from the outset. She added that the successful establishment of Evox’s process and methods in Bristol reflects the strength of the collaboration and provides a clear foundation for the program’s next stage.